Pontarollo Giulia, Acquasaliente Laura, Peterle Daniele, Frasson Roberta, Artusi Ilaria, De Filippis Vincenzo
From the Department of Pharmaceutical and Pharmacological Sciences, University of Padua, via Marzolo 5, Padua 35131, Italy.
From the Department of Pharmaceutical and Pharmacological Sciences, University of Padua, via Marzolo 5, Padua 35131, Italy
J Biol Chem. 2017 Sep 15;292(37):15161-15179. doi: 10.1074/jbc.M117.795245. Epub 2017 Jul 6.
Blood coagulation is a finely regulated physiological process culminating with the factor Xa (FXa)-mediated conversion of the prothrombin (ProT) zymogen to active α-thrombin (αT). In the prothrombinase complex on the platelet surface, FXa cleaves ProT at Arg-271, generating the inactive precursor prethrombin-2 (Pre2), which is further attacked at Arg-320-Ile-321 to yield mature αT. Whereas the mechanism of physiological ProT activation has been elucidated in great detail, little is known about the role of bacterial proteases, possibly released in the bloodstream during infection, in inducing blood coagulation by direct proteolytic ProT activation. This knowledge gap is particularly concerning, as bacterial infections are frequently complicated by severe coagulopathies. Here, we show that addition of subtilisin (50 nm to 2 μm), a serine protease secreted by the non-pathogenic bacterium , induces plasma clotting by proteolytically converting ProT into active σPre2, a nicked Pre2 derivative with a single cleaved Ala-470-Asn-471 bond. Notably, we found that this non-canonical cleavage at Ala-470-Asn-471 is instrumental for the onset of catalysis in σPre2, which was, however, reduced about 100-200-fold compared with αT. Of note, σPre2 could generate fibrin clots from fibrinogen, either in solution or in blood plasma, and could aggregate human platelets, either isolated or in whole blood. Our findings demonstrate that alternative cleavage of ProT by proteases, even by those secreted by non-virulent bacteria such as , can shift the delicate procoagulant-anticoagulant equilibrium toward thrombosis.
血液凝固是一个精细调节的生理过程,最终以因子Xa(FXa)介导的凝血酶原(ProT)酶原转化为活性α-凝血酶(αT)为终点。在血小板表面的凝血酶原酶复合物中,FXa在精氨酸-271处切割ProT,产生无活性的前体凝血酶原-2(Pre2),Pre2在精氨酸-320-异亮氨酸-321处进一步被切割,产生成熟的αT。虽然生理性ProT激活的机制已得到详细阐明,但对于细菌蛋白酶在感染期间可能释放到血液中,通过直接蛋白水解ProT激活来诱导血液凝固的作用知之甚少。这个知识空白尤其令人担忧,因为细菌感染常常并发严重的凝血病。在这里,我们表明添加枯草杆菌蛋白酶(50纳米至2微米),一种由非致病细菌分泌的丝氨酸蛋白酶,通过将ProT蛋白水解转化为活性σPre2来诱导血浆凝固,σPre2是一种有缺口的Pre2衍生物,具有单个切割的丙氨酸-470-天冬酰胺-471键。值得注意的是我们发现丙氨酸-470-天冬酰胺-471处的这种非经典切割对σPre2催化作用的起始至关重要,然而与αT相比,其催化作用降低了约100 - 200倍。值得注意的是,σPre2可以在溶液或血浆中从纤维蛋白原生成纤维蛋白凝块,并且可以聚集分离的或全血中的人血小板。我们的研究结果表明,蛋白酶对ProT的替代切割,即使是由无毒细菌如 分泌的蛋白酶,也可使微妙的促凝 - 抗凝平衡向血栓形成方向转变。
J Biol Chem. 2011-4-29
J Biol Chem. 2006-1-13
J Biol Chem. 2006-1-13
Proc Natl Acad Sci U S A. 2009-5-12
Int J Mol Sci. 2022-12-31
Comput Struct Biotechnol J. 2021-10-12
J Biol Chem. 2015-9-11
Proc Natl Acad Sci U S A. 2014-5-27
J Mol Biol. 2013-12-5